Cinven has well-defined investment criteria that capitalise on our proven value creation strategies and the knowledge of our sector teams. We invest in high quality companies that require a Cinven equity stake of €100 million or more. We look for businesses that allow us to utilise our investment strategies to create value.
Cinven's portfolio companies typically have the benefits of scale, product and price leadership, and given their size and profile, can attract highly capable management teams from around the world. Since the firm was founded in 1977, we have completed transactions valued at in excess of €70 billion.
|Name||Activity||Country||Acquired||Deal size (m)|
|AMCo||Niche speciality pharmaceuticals||UK, Global||Aug 2012/
|Bioclinica||Clinical Trials||US, Global||Oct 2016||-|
|Medpace||Contract research organisation||US, Global||Apr 2014||US$915|
|Synlab||Clinical diagnostic laboratories||Europe, Global||Aug 2015/Oct 2015||€2,900|